Pacira BioSciences (PCRX) Asset Writedowns and Impairment (2011 - 2022)
Pacira BioSciences (PCRX) recorded quarterly Asset Writedowns and Impairment of $16.1 million in Q4 2022, up 1052.43% quarter-over-quarter from $1.4 million in Q4 2011.
Pacira BioSciences (PCRX) Asset Writedowns and Impairment (2011 - 2022) Analysis & Trends
Pacira BioSciences' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $16.1 million for Q4 2022.
- In Q4 2022, Asset Writedowns and Impairment changed N/A year-over-year to $16.1 million; the TTM figure through Dec 2025 stood at $16.1 million (down 7.98% YoY), while the FY2025 annual figure was $25.9 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $16.1 million for Q4 2022 at Pacira BioSciences, up from $1.4 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $16.1 million in Q4 2022 to a low of $16.1 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Pacira BioSciences | 940.31 Mn | 738.13 Mn | 140.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 16.13 Mn |
| Dec 31, 2022 | 16.13 Mn |
| Dec 31, 2011 | 1.40 Mn |
| Dec 31, 2011 | 1.40 Mn |